

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

August 1, 2025

Consolidated Financial Results for the Three Months Ended June 30, 2025 (Under Japanese GAAP)



Company name: Mochida Pharmaceutical Co., Ltd.
 Listing: Tokyo Stock Exchange
 Securities code: 4534
 URL: <https://www.mochida.co.jp/english/>
 Representative: (Name) Naoyuki Mochida (Title) Representative Director, President
 Inquiries: (Name) Kenichi Miyamoto (Title) Head of Finance & Accounting Department
 Telephone: +81-3-3358-7211
 Scheduled date to commence dividend payments: -
 Preparation of supplementary material on financial results: None
 Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2025 (from April 1, 2025 to June 30, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2025	26,631	4.8	2,572	17.5	2,783	17.6	1,894	21.8
June 30, 2024	25,407	2.7	2,189	(13.0)	2,367	(8.7)	1,554	(7.9)

Note: Comprehensive income For the three months ended June 30, 2025: ¥1,875 million [121.1%]
 For the three months ended June 30, 2024: ¥848 million [(65.0)%]

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2025	53.43	-
June 30, 2024	43.85	-

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
June 30, 2025	161,743	131,152	81.1
March 31, 2025	160,121	130,694	81.6

Reference: Equity

As of June 30, 2025: ¥131,152 million
 As of March 31, 2025: ¥130,694 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	-	40.00	-	40.00	80.00
Fiscal year ending March 31, 2026	-				
Fiscal year ending March 31, 2026 (Forecast)		40.00	-	40.00	80.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	110,500	5.1	7,000	(13.9)	7,500	(7.0)	5,400	(5.0)	152.33

Note: Revisions to the financial result forecast most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period: None

Newly included: - companies (Company name)

Excluded: - companies (Company name)

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: Yes

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2025	36,390,000 shares
As of March 31, 2025	36,390,000 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2025	939,541 shares
As of March 31, 2025	939,531 shares

(iii) Average number of shares outstanding during the period (cumulative)

Three months ended June 30, 2025	35,450,466 shares
Three months ended June 30, 2024	35,451,376 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Explanation of the proper use of financial result forecasts and other special matters

The financial result forecasts presented in this document are based on information that is currently available to the Company as of the announcement of this document, and the Company does not guarantee to achieve them. In addition, actual financial results may differ significantly from these forecasts due to a wide range of factors.

Quarterly Consolidated Financial Statements

(1) Quarterly Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2025	As of June 30, 2025
Assets		
Current assets		
Cash and deposits	45,154	51,696
Accounts receivable - trade	31,617	29,945
Securities	5,996	2,996
Merchandise and finished goods	20,686	21,301
Work in process	2,295	1,802
Raw materials and supplies	10,314	11,018
Other	3,604	2,699
Total current assets	119,669	121,460
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	6,519	6,621
Machinery, equipment and vehicles, net	1,775	1,705
Land	6,046	6,046
Other, net	1,598	1,469
Total property, plant and equipment	15,940	15,842
Intangible assets	920	1,032
Investments and other assets		
Investment securities	15,022	15,031
Retirement benefit asset	355	352
Deferred tax assets	1,851	1,924
Other	6,362	6,099
Total investments and other assets	23,591	23,407
Total non-current assets	40,452	40,282
Total assets	160,121	161,743

(Millions of yen)

	As of March 31, 2025	As of June 30, 2025
Liabilities		
Current liabilities		
Notes and accounts payable - trade	7,419	8,851
Electronically recorded obligations - operating	1,241	1,313
Income taxes payable	1,510	996
Provision for bonuses	2,320	1,015
Other provisions	143	104
Other	12,266	13,835
Total current liabilities	24,902	26,117
Non-current liabilities		
Retirement benefit liability	3,690	3,643
Other	833	830
Total non-current liabilities	4,523	4,473
Total liabilities	29,426	30,590
Net assets		
Shareholders' equity		
Share capital	7,229	7,229
Capital surplus	1,871	1,871
Retained earnings	116,114	116,590
Treasury shares	(3,267)	(3,267)
Total shareholders' equity	121,947	122,423
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	8,162	8,181
Remeasurements of defined benefit plans	584	547
Total accumulated other comprehensive income	8,747	8,728
Total net assets	130,694	131,152
Total liabilities and net assets	160,121	161,743

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statements of Income

Three Months Ended June 30

(Millions of yen)

	For the three months ended June 30, 2024	For the three months ended June 30, 2025
Net sales	25,407	26,631
Cost of sales	12,451	13,005
Gross profit	12,955	13,626
Selling, general and administrative expenses	10,766	11,053
Operating profit	2,189	2,572
Non-operating income		
Interest income	0	15
Dividend income	203	236
Other	29	33
Total non-operating income	234	285
Non-operating expenses		
Interest expenses	0	0
Share of loss of entities accounted for using equity method	24	18
Foreign exchange losses	25	49
Other	6	6
Total non-operating expenses	56	75
Ordinary profit	2,367	2,783
Extraordinary income		
Gain on sale of non-current assets	1	—
Total extraordinary income	1	—
Extraordinary losses		
Loss on sale and retirement of non-current assets	4	0
Total extraordinary losses	4	0
Profit before income taxes	2,364	2,782
Income taxes	809	888
Profit	1,554	1,894
Profit attributable to owners of parent	1,554	1,894

Quarterly Consolidated Statements of Comprehensive Income

Three Months Ended June 30

(Millions of yen)

	For the three months ended June 30, 2024	For the three months ended June 30, 2025
Profit	1,554	1,894
Other comprehensive income		
Valuation difference on available-for-sale securities	(687)	19
Remeasurements of defined benefit plans, net of tax	(18)	(37)
Total other comprehensive income	(706)	(18)
Comprehensive income	848	1,875
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	848	1,875

Sales of Major Products

(Three months ended June 30, 2025)

(Billions of yen)

Products	Fiscal year ended March 31, 2025		Fiscal year ending March 31, 2026		Three months Y o Y change
	Apr-Jun	Apr-Mar	Apr-Jun	Apr-Mar forecast	
Treatment of ulcerative colitis Lialda	3.7	15.1	4.0	15.1	+ 8%
Treatment for chronic constipation Goofice	2.0	8.3	2.2	9.0	+ 9%
Treatment for chronic constipation Movicol	1.5	6.6	1.7	6.6	+ 10%
Treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease Treprost	1.0	4.2	1.3	5.9	+ 34%
Gout and hyperuricemia Urece	1.0	4.6	1.3	5.6	+ 25%
Drug for hyperlipidemia and arteriosclerosis obliterans Epadel	1.5	4.8	1.1	3.6	△ 27%
Treatment of ulcerative colitis Cortiment	0.0	0.5	0.1	1.7	+ 92%
Anticoagulant agent Heparin Sodium MOCHIDA	0.3	1.3	0.3	1.3	+ 5%
Generic drugs	7.2	31.3	7.7	34.8	+ 7%
Therapeutic agent for endometriosis, adenomyosis and dysmenorrhea Dienogest	2.3	10.5	2.8	11.9	+ 18%
Skin Care Products	1.6	7.1	1.9	7.4	+ 14%

Development Pipeline

【Ethical drug】

Development code 〈Generic name〉	Stage	Indications	Formulation	Remarks 〈Development country〉
* MD-0901 〈mesalazine〉	Approved	Ulcerative colitis (pediatric indication)	Oral	Licensed-in from Takeda Pharmaceuticals U.S.A., Inc. In-house development 〈Japan〉
RGB-19 〈tocilizumab〉	Filed	Rheumatoid Arthritis	Injection	Biosimilar Licensed-in from Gedeon Richter Plc. 〈Japan〉
FYU-981 〈dotinurad〉	Phase III	Gout and hyperuricemia (pediatric indication)	Oral	Co-development with FUJI YAKUHIN Co., Ltd. 〈Japan〉
MD-352 〈dienogest formulation〉	Phase II/III	Dysmenorrhea	Oral	In-house development 〈Japan〉
MD-712 〈treprostinil〉	Phase II/III	Pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease	Dry Powder Inhaler	Licensed-in from United Therapeutics Corporation In-house development 〈Japan〉
MND-21 〈icosapent〉	Filed	Hypertriglyceridemia	Oral	Collaboration on development with Sumitomo Pharma (Suzhou) Co., Ltd. 〈China〉

【Medical device】

Development code 〈Product name〉	Stage	Intended use or indications	Remarks 〈Development country〉
* dMD-001 〈Mochi-Gel〉	Approved	Articular cartilage lesion	In-house development 〈Japan〉
dMD-002	Therapeutic confirmatory study	Cavernous nerve injury	In-house development 〈Japan〉
dMD-003	Therapeutic confirmatory study	Post-operative adhesion	In-house development 〈Japan〉

Stages of Medical devices are classified into “Therapeutic exploratory study” and “Therapeutic confirmatory study”.

* Updates from May 12, 2025